Breast Recurrence Score Test Market Players:
- Genomic Health, Inc.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Agendia, Inc.
- NanoString Technologies, Inc.
- Myriad Genetics, Inc.
- Thermo Fisher Scientific, Inc.
- Illumina, Inc.
- Roche Holdings AG
- Biotheranostics, Inc.
- Qiagen N.V.
- Veracyte, Inc.
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
In the year 2026, the industry size of breast recurrence score test is estimated at USD 4.4 billion.
The global breast recurrence score test market size was more than USD 4.16 billion in 2025 and is anticipated to grow at a CAGR of over 6.3%, reaching USD 7.66 billion revenue by 2035.
The Asia Pacific region in the breast recurrence score test market is set to command a leading 38% share by 2035, underpinned by the shift toward patient-centered care.
Key players in the market include Genomic Health, Inc., Agendia, Inc., NanoString Technologies, Inc., Myriad Genetics, Inc., Thermo Fisher Scientific, Inc., Illumina, Inc.
